small molecule

NEXPLANON

ETONOGESTREL

Loss of exclusivityJuly 2030latest FDA-listed patent expiry

CompanyOrganon →View the full company profile on CliffBio

Drug detail

Brand name	NEXPLANON
Active ingredient	ETONOGESTREL
Strength	68MG/IMPLANT
Dosage form	IMPLANT
Route	IMPLANTATION
Modality	Small molecule
FDA approval	May 2011
Marketing status	RX

Listed patents

Patent	Expires	Type
9757552	July 2030	product
8722037	September 2027	product
10821277	May 2027	product
8888745	August 2026	product

Regulatory exclusivity

Code	Expires
D-199	January 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Organon